MRNA therapy takes on hormone deficiency
NCT ID NCT07197450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an mRNA drug called XH02 in 6 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone (PTH). The drug is designed to instruct cells to produce PTH after being given through a vein. The main goal is to check safety, while also measuring hormone and mineral levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA drug XH02 (PTH1-84 mRNA)
- What this could lead to
- If it works, this could point toward a new way to treat hypoparathyroidism by replacing the missing hormone without daily injections.
- What could go wrong
- This is a very early, tiny trial with only 6 people. It is mainly checking safety, not yet proving the drug works. The approach is new and may fail or cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder